Relationship between lipid profile parameters, coagulation system and inflammation markers in patients with hypertension and multifocal atherosclerosis

Aim. To establish the relationship between lipid profile parameters, coagulation system and inflammation markers in patients with hypertension (HTN) and multifocal atherosclerosis (MFA).

Material and methods. The study included 110 patients with HTN and MFA with a median age of 59 (51,0;64,3) years. Of these, 15 patients achieved target lowdensity lipoprotein cholesterol (LDL-C) <1,8 mmol/l (group 1), and 95 patients had LDL-C >1,8 mmol/l (group 2). Patients in both groups received lipid-l owering and comparable antihypertensive, antiplatelet therapy. To identify coagulation disorders, a test was performed on the T-2 Thrombodynamics Analyser System (OOO GemaCor, Moscow, Russia). All study participants were assessed for levels of high-sensitivity C-reactive protein and interleukin-6.

Results. Despite the lipid-l owering therapy, most patients with HTN and MFA (86,4%) did not achieve target LDL-C <1,8 mmol/l. In patients of group 2, compared to group 1, more pronounced procoagulant shifts were noted. The clot growth rate and the permanent clot growth rate were shifted to the hypercoagulation (28,6 μm/min vs 27 μm/min). Correlations between the studied parameters were also revealed. In group 1, the LDL-C level had a moderate direct correlation with the initial clot growth rate (r1=0,54, p1=0,04) and clot density (r1=0,55, p1=0,03), while in group 2, the concentrations of total cholesterol and LDL-C correlated with clot growth delay (r2=-0,22, p2=0,03 and r2=-0,21, p2=0,04, respectively).

Conclusion. In patients with HTN and MFA, complex relationships between lipid parameters, coagulation parameters, and inflammatory markers are observed, especially in the group with unachieved lipid target levels. Extra efforts are needed to identify patients with HTN and MFA in clinical practice and to prescribe optimal lipid-lowering therapy. In addition to lipid parameters, correction of other disorders (hemostasis, inflammation) that may affect the prognosis is necessary.

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-r epresentative studies with 104 million participants. Lancet. 2021; 398(10304):957-80. doi:10.1016/S0140-6736(21)01330-1.

2. Gallo G, Volpe M, Savoia C. Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. Front Med (Lausanne). 2022;8:798958. doi:10.3389/fmed.2021.798958.

3. Vlasov TD, Nesterovich II, Shimanski DA. Endothelial dysfunction: from the parti cular to the general. Return to the "Old Paradigm"? Regional blood circulation and microcirculation. 2019;18(2):19-27. (In Russ.)

4. Ning B, Chen Y, Waqar AB, et al. Hypertension Enhances Advanced Atherosclerosis and Induces Cardiac Death in Watanabe Heritable Hyperlipidemic Rabbits. Am J Pathol. 2018;188(12):2936-47. doi:10.1016/j.ajpath.2018.08.007.

5. Steg PG, Bhatt DL, Wilson PW, et al. REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197-206. doi:10.1001/jama.297.11.1197.

6. Touyz RM, Yao G, Schiffrin EL. c-Src induces phosphorylation and translocation of p47phox: role in superoxide generation by angiotensin II in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23(6):981-7. doi:10.1161/01.ATV.0000069236.27911.68.

7. Đukanović N, Obradović S, Zdravković M, et al. Lipids and Antiplatelet Therapy: Important Considerations and Future Perspectives. Int J Mol Sci. 2021;22(6):3180. doi:10.3390/ijms22063180.

8. Dolgushin II, Genkel VV, Shaposhnik II, et al. Intensity of CD36 expression by monocyte subpopulations and blood lipid spectrum parameters in patients without established atherosclerotic cardiovascular disease. Sibirskiy nauchnyy meditsinskiy zhurnal = Siberian Scientific Medical Journal. 2021;41(4):58-65. (In Russ.)

9. Held C, White HD, Stewart RAH, et al. STABILITY Investigators. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017;6(10):e005077. doi:10.1161/JAHA.116.005077.

10. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.)

11. Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.)

12. Ezhov MV, Akhmedzhanov NM, Kolmakova TE, et al. Outpatient Practice of Lipid-Lowering Therapy Prescription (According to the ARGO-3 Study). Rational Pharmacotherapy in Cardiology. 2023;19(2):143-50. (In Russ.)

13. Peterson BE, Bhatt DL, Ballantyne CM, et al. GOULD Investigators. Intensity of Lipid-Lowering Therapy Among Patients With Polyvascular Disease. JAMA NetwOpen. 2023;6(3):e234709. doi:10.1001/jamanetworkopen.2023.4709.

14. Arutyunov GP, Tarlovskaya EI, Arutyunov AG, et al. Peculiarities of polyvascular disease and the diagnostic significance of the ankle-brachial index in patients with coronary artery disease: results from the real-world registry KAMMA (Clinical registry on patient population with polyvascular disease in the Russian Federation and Eurasian countries). Russian Journal of Cardiology. 2024;29(4):5837. (In Russ.)

15. Arutyunov AG, Batluk TI, Bashkinov RA, et al. Multifocal atherosclerosis: focus on the prevention of ischemic events. Russian Journal of Cardiology. 2021;26(12):4808. (In Russ.)

16. Zhang Z, Rodriguez M, Zheng Z. Clot or Not? Reviewing the Reciprocal Regulation Between Lipids and Blood Clotting. Arterioscler Thromb Vasc Biol. 2024;44(3):533-44. doi:10.1161/ATVBAHA.123.318286.

17. Kott KA, Morel-K opp MC, Vernon ST, et al. Association of Global Coagulation Profiles With Cardiovascular Risk Factors and Atherosclerosis: A Sex Disaggregated Analysis From the BioHEART-CT Study. J Am Heart Assoc. 2021;10(20):e020604. doi:10.1161/JAHA.120.020604.

18. Morishita E, Minami S, Ishino C, et al. Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia. J Atheroscler Thromb. 2002;9(1):72-7. doi:10.5551/jat.9.72.

19. Siniscalchi C, Basaglia M, Riva M, et al. Statins Effects on Blood Clotting: A Review. Cells. 2023;12(23):2719. doi:10.3390/cells12232719.